Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinco Pharmaceutical Holdings's quarterly market cap
declined
from Dec. 2024 (HK$400 Mil) to Jun. 2025 (HK$364 Mil) and
declined
from Jun. 2025 (HK$364 Mil) to Dec. 2025 (HK$360 Mil).
Sinco Pharmaceutical Holdings's annual market cap
declined
from Dec. 2023 (HK$488 Mil) to Dec. 2024 (HK$400 Mil) and
declined
from Dec. 2024 (HK$400 Mil) to Dec. 2025 (HK$360 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sinco Pharmaceutical Holdings's Enterprise Value for Today is HK$257 Mil.
Sinco Pharmaceutical Holdings (HKSE:06833) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sinco Pharmaceutical Holdings Market Cap Related Terms
Sinco Pharmaceutical Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06833 vs MCK, COR, CAH: Market Cap Comparison
For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinco Pharmaceutical Holdings Market Cap vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Sinco Pharmaceutical Holdings's Market Cap falls into.
Sinco Pharmaceutical Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinco Pharmaceutical Holdings (HKSE:06833) has a Market Cap of HK$339 Mil as of Aug. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sinco Pharmaceutical Holdings and its competitors. According to the industry distribution chart, Sinco Pharmaceutical Holdings ranks #84 out of 123 companies in the Medical Distribution industry, placing it in the top 68.3%.
Is Sinco Pharmaceutical Holdings' Market Cap too high?
Sinco Pharmaceutical Holdings' current Market Cap is HK$339 Mil. Based on the distribution chart, Sinco Pharmaceutical Holdings ranks #84 out of 123 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sinco Pharmaceutical Holdings has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinco Pharmaceutical Holdings' Market Cap compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinco Pharmaceutical Holdings ranks #84 out of 123 companies for Market Cap. This places Sinco Pharmaceutical Holdings in the lower half of its industry. The industry median Market Cap is 137.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Distribution company?
The median Market Cap among Medical Distribution companies is 137.06, based on 123 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sinco Pharmaceutical Holdings and its competitors. For the Medical Distribution industry, the median Market Cap is 137.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinco Pharmaceutical Holdings's current Market Cap is HK$339 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinco Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings (HKSE:06833) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.17 — trading 12.6% below its estimated fair value. The current Market Cap is HK$339 Mil. Sinco Pharmaceutical Holdings' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sinco Pharmaceutical Holdings (HKSE:06833), the current Market Cap is HK$339 Mil as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinco Pharmaceutical Holdings (HKSE:06833) Overvalued in 2026?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of HK$0.17 is trading 12.6% below its estimated GF Value™ of HK$0.19.
GuruFocus considers Sinco Pharmaceutical Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:06833:
Market Cap: HK$339 Mil
GF Value™: HK$0.19 vs. price of HK$0.17 (12.6% below fair value)
No single metric tells the full story. See the HKSE:06833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
44GF Score
Get the complete analysis for HKSE:06833
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06833 has been successfully added to your 
